[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515182":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":45,"collaborators":28,"id":48,"slug":28,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":28,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":28,"enrollmentInfo":56,"targetDuration":28,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":28,"overallStatus":66,"whyStopped":28,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Beijing Friendship Hospital","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"Carrimycin tablets","EXPERIMENTAL",[12],"Drug: Carrimycin tablets",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"DRUG","Carrimycin tablets are administered 400mg a day orally for 7 days.",[9],[19],"Carrimycin",[21],{"name":22,"affiliation":5,"role":23},"Zhao Wang, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":28,"email":29},"CONTACT","63138303",null,"wangzhao@ccmu.edu.cn",[31],{"facility":32,"status":28,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Beijing Friendship Hospital, Capital Medical University","Beijing","Beijing Municipality","100050","China",{"type":38,"coordinates":39},"Point",[40,41],116.39723,39.9075,{"lat":41,"lon":40},[44],{"name":22,"role":26,"phone":27,"phoneExt":28,"email":29},{"type":23,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Zhao Wang","Professor and Head of hematology","100515182",false,"NCT05988177","Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections","Clinical Study on the Efficacy and Safety of Carrimycin Tablets in Hemophagocytic Lymphohistiocytosis Patients With Carbapenem-resistant Infections","Inclusion Criteria:\n\n* Met HLH-2004 diagnostic criteria;\n* Active infection；\n* Empirical treatment with carbapenems did not respond after 72 hours；\n* Age \\>18 years old, no gender limitation;\n* Ability and willingness to adhere to the study visit schedule and all protocol requirements.\n\nExclusion Criteria:\n\n* Other antibiotics should be selected according to the results of drug sensitivity；\n* Systemic antibiotics other than carbapenems are used with 72 hours；\n* Inability to take oral medications due to disease of gastrointestinal tract；\n* Severe liver insufficiency;\n* Expected survival time \\\u003C 1 month;\n* Pregnant or breasting-feeding women;\n* Allergic to Carrimycin tablets;\n* Active hepatitis B or hepatitis C infection;\n* Patients with HIV infection;\n* Patients with other contraindications considered unsuitable for participation in this study.","ALL","18 Years",{"count":57,"type":58},20,"ESTIMATED","INTERVENTIONAL",[61],"NA","This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.",[64,65],"Carbapenem Resistant Bacterial Infection","Hemophagocytic Lymphohistiocytoses","NOT_YET_RECRUITING","2023-08-04",{"date":69,"type":70},"2023-08-14","ACTUAL",{"date":72,"type":58},"2023-08-30",{"date":74,"type":58},"2026-12-30",{"name":5,"class":6},1]